NCT01873534View on ClinicalTrials.gov

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Anemia of Chronic Disease
Interventions
DRUG

FMX-8

FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.

Trial Locations (2)

55404

DaVita Minneapolis Dialysis Unit, Minneapolis

80005

DaVita Arvada Dialysis Center, Arvada

Sponsors

Collaborators (1)

Davita Clinical Research
All Listed Sponsors
collaborator

Davita Clinical Research

INDUSTRY

lead

FerruMax Pharmaceuticals, Inc.

INDUSTRY